AIMS/HYPOTHESIS: The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotrophic peptide (GIP) are released from intestinal endocrine cells in response to luminal glucose. Glucokinase is present in these cells and has been proposed as a glucose sensor. The physiological role of glucokinase can be tested using individuals with heterozygous glucokinase gene (GCK) mutations. If glucokinase is the gut glucose sensor, GLP-1 and GIP secretion during a 75 g OGTT would be lower in GCK mutation carriers compared with controls. METHODS: We compared GLP-1 and GIP concentrations measured at five time-points during a 75 g OGTT in 49 participants having GCK mutations with those of 28 familial controls. Mathematical modelling of glucose, insulin and C-peptide was used to estimate basal insulin secretion rate (BSR), total insulin secretion (TIS), beta cell glucose sensitivity, potentiation factor and insulin secretion rate (ISR). RESULTS: GIP and GLP-1 profiles during the OGTT were similar in GCK mutation carriers and controls (p = 0.52 and p = 0.44, respectively). Modelled variables of beta cell function showed a reduction in beta cell glucose sensitivity (87 pmol min(-1) m(-2) [mmol/l](-1) [95% CI 66-108] vs 183 pmol min(-1) m(-2) [mmol/l](-1) [95% CI 155-211], p < 0.001) and potentiation factor (1.5 min [95% CI 1.2-1.8] vs 2.2 min [95% CI 1.8-2.7], p = 0.007) but no change in BSR or TIS. The glucose/ISR curve was right-shifted in GCK mutation carriers. CONCLUSIONS/ INTERPRETATION: Glucokinase, the major pancreatic glucose sensor, is not the main gut glucose sensor. By modelling OGTT data in GCK mutation carriers we were able to distinguish a specific beta cell glucose-sensing defect. Our data suggest a reduction in potentiation of insulin secretion by glucose that is independent of differences in incretin hormone release.
AIMS/HYPOTHESIS: The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotrophic peptide (GIP) are released from intestinal endocrine cells in response to luminal glucose. Glucokinase is present in these cells and has been proposed as a glucose sensor. The physiological role of glucokinase can be tested using individuals with heterozygous glucokinase gene (GCK) mutations. If glucokinase is the gut glucose sensor, GLP-1 and GIP secretion during a 75 g OGTT would be lower in GCK mutation carriers compared with controls. METHODS: We compared GLP-1 and GIP concentrations measured at five time-points during a 75 g OGTT in 49 participants having GCK mutations with those of 28 familial controls. Mathematical modelling of glucose, insulin and C-peptide was used to estimate basal insulin secretion rate (BSR), total insulin secretion (TIS), beta cell glucose sensitivity, potentiation factor and insulin secretion rate (ISR). RESULTS:GIP and GLP-1 profiles during the OGTT were similar in GCK mutation carriers and controls (p = 0.52 and p = 0.44, respectively). Modelled variables of beta cell function showed a reduction in beta cell glucose sensitivity (87 pmol min(-1) m(-2) [mmol/l](-1) [95% CI 66-108] vs 183 pmol min(-1) m(-2) [mmol/l](-1) [95% CI 155-211], p < 0.001) and potentiation factor (1.5 min [95% CI 1.2-1.8] vs 2.2 min [95% CI 1.8-2.7], p = 0.007) but no change in BSR or TIS. The glucose/ISR curve was right-shifted in GCK mutation carriers. CONCLUSIONS/ INTERPRETATION:Glucokinase, the major pancreatic glucose sensor, is not the main gut glucose sensor. By modelling OGTT data in GCK mutation carriers we were able to distinguish a specific beta cell glucose-sensing defect. Our data suggest a reduction in potentiation of insulin secretion by glucose that is independent of differences in incretin hormone release.
Authors: F Matschinsky; Y Liang; P Kesavan; L Wang; P Froguel; G Velho; D Cohen; M A Permutt; Y Tanizawa; T L Jetton Journal: J Clin Invest Date: 1993-11 Impact factor: 14.808
Authors: T L Jetton; Y Liang; C C Pettepher; E C Zimmerman; F G Cox; K Horvath; F M Matschinsky; M A Magnuson Journal: J Biol Chem Date: 1994-02-04 Impact factor: 5.157
Authors: A Stride; M Vaxillaire; T Tuomi; F Barbetti; P R Njølstad; T Hansen; A Costa; I Conget; O Pedersen; O Søvik; R Lorini; L Groop; P Froguel; A T Hattersley Journal: Diabetologia Date: 2002-03 Impact factor: 10.122
Authors: Hyeung-Jin Jang; Zaza Kokrashvili; Michael J Theodorakis; Olga D Carlson; Byung-Joon Kim; Jie Zhou; Hyeon Ho Kim; Xiangru Xu; Sic L Chan; Magdalena Juhaszova; Michel Bernier; Bedrich Mosinger; Robert F Margolskee; Josephine M Egan Journal: Proc Natl Acad Sci U S A Date: 2007-08-27 Impact factor: 11.205
Authors: Rachel M Freathy; M Geoffrey Hayes; Margrit Urbanek; Lynn P Lowe; Hoon Lee; Christine Ackerman; Timothy M Frayling; Nancy J Cox; David B Dunger; Alan R Dyer; Andrew T Hattersley; Boyd E Metzger; William L Lowe Journal: Diabetes Date: 2010-08-03 Impact factor: 9.461
Authors: A M C Simonis-Bik; D I Boomsma; J M Dekker; M Diamant; E J C de Geus; L M 't Hart; R J Heine; M H H Kramer; J A Maassen; A Mari; A Tura; G Willemsen; E M W Eekhoff Journal: Diabetologia Date: 2011-02-11 Impact factor: 10.122
Authors: Benjamin G Challis; Julie Harris; Alison Sleigh; Iona Isaac; Steve M Orme; Nandini Seevaratnam; Ketan Dhatariya; Helen L Simpson; Robert K Semple Journal: Clin Endocrinol (Oxf) Date: 2014-07-02 Impact factor: 3.478
Authors: J Hulín; M Škopková; T Valkovičová; S Mikulajová; M Rosoľanková; P Papcun; D Gašperíková; J Staník Journal: Physiol Res Date: 2020-11-02 Impact factor: 1.881